Document is current

Article History

Accepted: 17 May 2025

First Online: 5 June 2025

Declarations

:

: The project titled “Outcomes following second allogeneic stem cell transplant for graft failure or poor graft function: a single centre experience” was reviewed by the University of British Columbia Research and Ethics Board Chair and the research project was found acceptable on ethical grounds for research involving human subjects and approval was granted (UBC CREB H22-03330). The initial approval date was June 1, 2023. The approval is renewed yearly and the current approval will expire on May 23, 2025. The need for signed consent from individual patient was waived as the risk to confidentiality was deemed minimal.

: Not applicable.

: Cherniawsky: Consultancy / Ad board: Astellas, Kite/Gilead, Abbvie. Speakers Honoraria: Astellas, Kite/Gilead.Mourad: Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Alexion: Consultancy; Paladin: Honoraria, Speakers Bureau.Chung: Takeda: Consultancy, Honoraria; Astella Pharma: Honoraria; Novartis: Honoraria; Paladin: Honoraria. Sanford: Astellas: Honoraria; AbbVie: Honoraria.Song: Novartis: Honoraria; Amgen: Honoraria; Sanofi: Honoraria; Janssen: Honoraria; GSK: Honoraria; BMS: Honoraria; Forus: Honoraria; Gilead: Honoraria.Stubbins: AbbVie: Consultancy, Honoraria; Jazz Pharmaceuticals: Honoraria; Pfizer: Honoraria.Toze: AbbVie: Honoraria, Research Funding; Beigene: Honoraria; Janssen: Honoraria; Astra-Zeneca: Research Funding.White: Novartis: Honoraria.All other authors have no potential conflicts to disclose.

: Artificial intenlligence tools were not used at any stage during the elaboration of this manucript.